ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

ACTU vs MCRB // OPERATING MARGIN

Actuate Therapeutics Inc. (NASDAQ) VS. Seres Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: ACTU 2 — MCRB 1
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ACTU VS. MCRB) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC ACTU MCRB SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — 4.42% — TIE /fcf-yield <GO>
Operating Margin ACTIVE — -60.00% — TIE /operating-margins <GO>
Net Profit Margin — 68.00% — TIE /net-margins <GO>
Revenue Growth (YoY) — — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 3/9 5/9 -2.00 MCRB /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 33.3 26.3 +7.00 ACTU /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $18.4M $17.8M $651.1K ACTU /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR ACTU REV MCRB REV ACTU GROSS % MCRB GROSS % ACTU FCF MCRB FCF
FY 2025 $63.0M $789.0K — — -$19.2M $865.0K
FY 2024 $70.5M $339.7M — — -$21.8M -$149.0M
FY 2023 $69.9M $546.3M — — -$21.6M -$117.4M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ACTU // BETA —
MCRB // BETA —